Atavistik Bio
PrivateLast Round
Series B
Extension
Mar 5, 2026
Total Funding Raised
$260M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Atavistik Bio operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B Extension round in March 2026.
Atavistik Bio is a biopharmaceutical company that discovers and develops precision allosteric small molecule therapeutics for metabolic diseases and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atavistik Bio Comparables
Compare Atavistik Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alterome Therapeutics | 88% | |
| HotSpot Therapeutics | 86% | |
| Frontier Medicines | 83% |
For institutional investors. Book with your work email.
Atavistik Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Mar 5, 2026 | ||||
| Series B | Dec 18, 2025 | ||||
| Series A Extension | Dec 19, 2023 | ||||
| Series A | Aug 24, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Atavistik Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series B Extension, Series A, Series B, Series A Extension |
| RA Capital Management | Series B Extension, Series B |
| Lux Capital | Series A, Series B Extension, Series B, Series A Extension |
| The Chernin Group | Series A, Series A Extension |
| Nextech Invest | Series A, Series B Extension, Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 109% MoM, reaching 4.1K.
- Mar 16, 2026
Agent ZE74-0282 is currently in Phase I clinical trials.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 28, 2026
Atavistik Bio, Inc. enters a collaboration with Roche to discover and develop allosteric small-molecule therapies against multiple targets using its AMPS allosteric drug discovery platform, including targets in cardiovascular, renal and metabolic diseases, on Sep 24th '26'.
- partners_withSep 25, 2026
Atavistik Bio, Inc. partnered with Novo Nordisk A/S on Sep 21st '26.
- partners_withSep 25, 2026
Atavistik Bio, Inc. and Genentech, Inc. partner in a platform-technology deal reported in Sep '26.
- is_developingSep 24, 2026
On Sep 24th '26, Atavistik Bio, Inc. continues to develop its own treatments for rare blood disorders, including hereditary hemorrhagic telangiectasia, which causes malformed blood vessels.
- is_developingSep 24, 2026
Atavistik Bio, Inc. enters a strategic research collaboration with Roche to discover and develop novel allosteric small molecule therapeutics against multiple cardiovascular, renal, and metabolic disease targets, leveraging its AMPS platform, in Massachusetts on Sep 24th '26.
For institutional investors. Book with your work email.
Atavistik Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Atavistik Bio's valuation, stock price, and market status.
Is Atavistik Bio a public or private company?
Atavistik Bio is a private company.
What is the current stock price of Atavistik Bio?
Atavistik Bio is a private company, so its shares have no public market price. Caplight tracks Atavistik Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Atavistik Bio worth (valuation)?
Valuation information for Atavistik Bio is not publicly available.
Can I buy Atavistik Bio stock?
Atavistik Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Atavistik Bio's last funding round?
Atavistik Bio's most recent funding round was Series B Extension on March 5, 2026.
Who are the main investors in Atavistik Bio?
Key investors in Atavistik Bio include The Column Group, RA Capital Management, Lux Capital, The Chernin Group, Nextech Invest.
Will Atavistik Bio IPO soon?
No public IPO plans have been announced for Atavistik Bio.
How can I track Atavistik Bio secondary market activity?
Caplight tracks bids, offers, and trades in Atavistik Bio's shares on secondary markets.